Copper status Abnormalities and how to measure them in neurodegenerative disorders

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 3, 2010, Pages 182-194

  Siotto, Mariacristina ^a   Bucossi, Serena ^a   Squitti, Rosanna ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Alzheimer's disease; Ceruloplasmin; Ceruloplasmin enzymatic activity; Copper; Copper serum analysis; Free copper; Neurodegenerative disorders

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CERULOPLASMIN; COPPER; CURCUMIN; METAL CHELATE;

ACERULOPLASMINEMIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALYTIC METHOD; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; ATOMIC EMISSION SPECTROMETRY; AUTOSOMAL RECESSIVE DISORDER; BIOLOGICAL MONITORING; COLORIMETRY; COPPER BLOOD LEVEL; COPPER METABOLISM; DEGENERATIVE DISEASE; ELECTROCHEMICAL ANALYSIS; HUMAN; HUNTINGTON CHOREA; IRON METABOLISM; MENKES SYNDROME; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID PHASE EXTRACTION; ULTRAFILTRATION; WILSON DISEASE; X RAY FLUORESCENCE;

ANIMALS; BIOLOGICAL MARKERS; CERULOPLASMIN; COPPER; HUMANS; NEURODEGENERATIVE DISEASES; NUTRITIONAL STATUS; PATENTS AS TOPIC; TECHNOLOGY, MEDICAL;

EID: 78649337090     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910793362395     Document Type: Article

References (148)

1. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990; 186: 1-85
2. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984; 219(1): 1-14
3. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase. Science 1999; 284(5415): 805-8
4. Stockel J, Safar J, Wallace AC, Cohen FE, Prusiner SB. Prion protein selectively binds copper(II) ions. Biochemistry 1998; 37(20): 7185-93
5. th ed. McGraw-Hill Inc.: New York 1989
6. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, et al. The cellular prion protein binds copper in vivo. Nature 1997; 390(6661): 684-7
7. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000; 4(2): 184-91
8. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis 1999; 6(4): 221-30
9. Desai V, Kaler SG. Role of copper in human neurological disorders. Am J Clin Nutr 2008; 88(3): 855S-8S
10. Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008; 4(3): 176-85
11. Squitti R, Salustri C. Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res 2009; 6(6): 476-87
12. Choi BS, Zheng W. Copper transport to the brain by the blood brain barrier and blood-CSF barrier. Brain Res 2009; 1248: 14-21
13. Iwase T, Nishimura M, Sugimura H, Igarashi H, Ozawa F, Shinmura K, et al. Localization of Menkes gene expression in the mouse brain; its association with neurological manifestations in Menkes model mice. Acta Neuropathol 1996; 91(5): 482-8
14. Qian Y, Tiffany-Castiglioni E, Welsh J, Harris ED. Copper efflux from murine microvascular cells requires expression of the menkes disease Cu-ATPase. J Nutr 1998; 128(8): 1276-82
15. Niciu MJ, Ma XM, El Meskini R, Ronnett GV, Mains RE, Eipper BA. Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. Neuroscience 2006; 139(3): 947-64
16. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006; 26: 7212-21
17. Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity, and memory. Prog Neurobiol 2003; 70: 1-32
18. Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 2004; 279: 51958-64
19. Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, et al. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 2003; 278: 17401-7
20. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Kea B. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002; 277: 44670-6
21. White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 1999; 842: 439-44
22. Bellingham SA, Ciccotosto GD, Needham BE, Fodero LR, White AR, Masters CL, et al. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem 2004; 91(2): 423-8
23. Bielli P, Calabrese L. Structure to function relationships in ceruloplasmin: A 'moonlighting' protein. Cell Mol Life Sci 2002; 59(9): 1413-27
24. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22: 439-58
25. Meyer LA, Durley AP, Prohaska JR, Harris ZL. Copper transport and metabolism are normal in aceruloplasminemic mice. J Biol Chem 2001; 276(39): 36857-61
26. Shim H, Harris ZL. Genetic defects in copper metabolism. J Nutr 2003;133(5 Suppl 1): 1527S-31S
27. Osaki S, Walaas O. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase. 3. Effects of deuterium and temperature on the enzymic oxidation of ferrous ion. Arch Biochem Biophys 1968; 125(3): 918-23
28. Osaki S, Johnson DA, Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241(12): 2746-51
29. Osaki S, Johnson DA, Frieden E. The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. J Biol Chem 1971; 246(9): 3018-23
30. Attieh ZK, Mukhopadhyay CK, Seshadri V, Tripoulas NA, Fox PL. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem 1999; 274(2): 1116-23
31. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005; 49(3): 633-40
32. Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003; 278(29): 27144-8
33. Linder MC, Houle PA, Isaacs E, Moor JR, Scott LE. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 1979; 24(1): 23-35
34. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006; 106(6): 1995-2044
35. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999; 222(3): 236-45
36. Hung YH, Bush AI, Cherny RA. Copper in the brain and Alzheimer's disease. J Biol Inorg Chem 2010;15(1): 61-76
37. Sato M, Ohtomo K, Daimon T, Sugiyama T, Iijima K. Localization of copper to afferent terminals in rat locus ceruleus, in contrast to mitochondrial copper in cerebellum. J Histochem Cytochem 1994; 42(12): 1585-91
38. Que EL, Domaille DW, Chang CJ. Metals in neurobiology: Probing their chemistry and biology with molecular imaging. Chem Rev 2008; 108(5): 1517-49
39. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res 1996; 738(2): 265-74
40. Chutkow JG. Evidence for uptake of nonceruloplasminic copper in the brain: Effect of ionic copper and amino acids. Proc Soc Exp Biol Med 1978; 158(1): 113-6
41. Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J Neural Transm 2000; 107(3): 321-9
42. Sperling MB, Welz B. Atomic Absorption Spectrometry. Wiley-VCH: Weinheim 1999
43. Alkemade CTJ, Hollander T, Snellman W, Zeegers PJT. Metal Vapours in flames. Pergamon Press: Oxford 1982
44. L'vov BV. Forty years of electrothermal atomic absorption spectrometry. Advances and problems in theory. Spectrochim Acta B 1997; 52: 1239-45
45. rd ed. Wiley-VCH: Weinheim, Germany 1998
46. Yebra-Biurrun MC, Cespon-Romero RM. Fast ultrasound-assisted extraction of copper, iron, manganese and zinc from human hair samples prior to flow injection flame atomic absorption spectrometric detection. Anal Bioanal Chem 2007; 388(3): 711-6
47. Hill SJ, Dawson JB, Evans EH, Fisher A, Price WJ, Smith CMM, et al. Advances in atomic emission absorption and fluorescence spectrometry, and related techniques. J Anal Atomic Spectrometry 2000; 15: 763-805
48. Renmin GD, Zhong K, Feng M, Liu X. Determination of trace copper in water samples by flame atomic absorption spectrometry after preconcentration on a phosphoric acid functionalized cotton chelator. J Serbian Chem Soc 2008; 73(2): 249-58
49. Feyime SM, Ataman OY. Effect of nitric acid for equal stabilization and sensitivity of different selenium species in electrothermal atomic absorption spectrometry. Anal Chem Acta 2005; 547: 126-31
50. Bertin EP. Principles and practice of X-ray spectrometric analysis. Kluwer Academic: Plenum Publishers 1975
51. Jarvis KE, Gray AL, Houk RS. Inductively Coupled Plasma Mass Spectrometry. Blackie: Glasgow 1992
52. Date AR, Gray AL. Inductively Coupled Plasma Mass Spectrometry. Blackie: Glasgow 1989
53. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper in serum. Clin Chem 1989; 35(4): 552-4
54. Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002; 59(8): 1153-61
55. Beckett JM, Hartley TF, Ball MJ. Evaluation of the Randox colorimetric serum copper and zinc assays against atomic absorption spectroscopy. Ann Clin Biochem 2009; 46(Pt 4): 322-6
56. Brenner AJ, Harris ED. A quantitative test for copper using bicinchoninic acid. Anal Biochem 1995; 226(1): 80-4
57. Infusino I, Valente C, Dolci A, Panteghini M. Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material. Anal Bioanal Chem 2010; 397(2): 521-5
58. Buffone GJ, Brett EM, Lewis SA, Iosefsohn M, Hicks JM. Limitations of immunochemical measurement of ceruloplasmin. Clin Chem 1979; 25(5): 749-51
59. Macintyre G, Gutfreund KS, Martin WR, Camicioli R, Cox DW. Value of an enzymatic assay for the determination of serum ceruloplasmin. J Lab Clin Med 2004; 144(6): 294-301
60. Walshe JM. Wilson's disease: The importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003; 40(Pt 2): 115-21
61. Hiyamuta, S., Shimizu, K., Kodota, A. Anti-human ceruloplasmin monoclonal antibody. US491066 (1996)
62. Si Houn, H., Young-Ju, J., Soo-Young, L., Ha-Cheol, S., Sun-Young, P., Eun-Sun. Y., Hee-Sung, H. Kit and method of screening Wilson's Disease. US7407743 (2008)
63. Adelstein SJ, Coombs TL, Vallee BL. Metalloenzymes and myocardial infarction. I. The relation between serum copper and ceruloplasmin and its catalytic activity. N Engl J Med 1956; 255(3): 105-9
64. Sunderman FW, Jr., Nomoto S. Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 1970; 16(11): 903-10
65. Mukerjee H. A kinetic method for determination of serum ceruloplasmin. Clin Chem 1990; 36(2): 391-2
66. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of odianisidine dihydrochloride. Clin Chem 1974; 20(12): 1556-63
67. Lehmann HP, Schosinsky KH, Beeler MF. Standardization of serum ceruloplasmin concentrations in international enzyme units with o-Dianisidine dihydrochloride as substrate. Clin Chem 1974; 20(12): 1564-7
68. Winkles J, Jones AF, Winyard P, Blake DR, Lunec J. An automated method for the kinetic measurement of ferroxidase activity. Ann Clin Biochem 1988; 25 (Pt 3): 250-4
69. Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998; 44(11): 2313-9
70. Fleming JJ, Santhosh S, Selvakumar R, Jose A, Eapen E. Usefulness of ferroxidase activity of ceruloplasmin in the diagnosis of Wilson's Disease. Indian J Clin Biochem 2009; 24(1): 15-22
71. Somani BL, Ambade V. A kinetic method amenable to automation for ceruloplasmin estimation with inexpensive and stable reagents. Clin Biochem 2007; 40(8): 571-4
72. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Adjusting copper concentrations for caeruloplasmin levels in routine clinical practice. J Clin Pathol 2006; 59(8): 867-9
73. Twomey PJ, Wierzbicki AS, House IM, Viljoen A, Reynolds TM. Percentage non-caeruloplasmin bound copper. Clin Biochem 2007; 40(9-10): 749-50
74. Bohrer D, Do Nascimento PC, Ramirez AG, Mendonca JK, De Carvalho LM, Pomblum SC. Comparison of ultrafiltration and solid phase extraction for the separation of free and protein-bound serum copper for the Wilson's disease diagnosis. Clin Chim Acta 2004; 345(1-2): 113-21
75. McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Am J Clin Pathol 2009; 131(2): 160-5
76. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 2008; 33(9): 1717-23
77. Kanzer SH, Althaus, J.S. Instruments for selective and direct detection of free metals in fluids and methods to diagnose metal related diseases and determine pharmacologic dosing regimens. WO2008046086 (2008)
78. Kanzer, S.H., Althaus, J.S. Instruments for direct detection of free metals in fluids and methods to diagnose metal-related diseases and determine pharmacologic dosing regimens. US20080268491 (2008)
79. Althaus, J.S., Kanzer, S.H. Methods and devices for the detection and measurement of free metals in fluids and methods for diagnosing metal-related diseases and for determining pharmacological dosing regimen. US20070209950 (2007)
80. Cox DW, Moore SD. Copper transporting P-type ATPases and human disease. J Bioenerg Biomembr 2002; 34(5): 333-8
81. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol 1998; 1(1): 85-98
82. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993; 197(1): 271-7
83. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5(4): 327-37
84. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5(4): 344-50
85. Scheinberg IH, Sternlieb I. Wilson's disease. Ann Rev Med 1965; 16: 119-34
86. Merle U, Weiss KH, Eisenbach C, Tuma S, Ferenci P, Stremmel W. Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. BMC Gastroenterol 2010; 10: 8
87. Merle U, Eisenbach C, Weiss KH, Tuma S, Stremmel W. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J Hepatol 2009; 51(5): 925-30
88. Hartard C, Weisner B, Dieu C, Kunze K. Wilson's disease with cerebral manifestation: Monitoring therapy by CSF copper concentration. J Neurol 1993; 241(2): 101-7
89. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192(1): 106-13
90. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992; 256(5054): 184-5
91. Crouch PJ, White AR, Bush AI. The modulation of metal bio availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J 2007; 274(15): 3775-83
92. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158(1): 47-52
93. Ma Q, Li Y, Du J, Liu H, Kanazawa K, Nemoto T, et al. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2006; 27(4): 841-9
94. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002; 277(43): 40302-8
95. Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 1999; 38(14): 4595-603
96. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994; 94(2): 860-9
97. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94(18): 9866-8
98. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008; 5(3): 421-32
99. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 2004; 279(19): 20378-86
100. Armendariz AD, Gonzalez M, Loguinov AV, Vulpe CD. Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol Genomics 2004; 20(1): 45-54
101. Lin R, Chen X, Li W, Han Y, Liu P, Pi R. Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: Blockage by curcumin. Neurosci Lett 2008; 440(3): 344-7
102. Hoogenraad T. Wilson's Disease. Intermed Medical Publisher: Amsterdam 2001
103. Squitti R, Ventriglia M, Barbati G, Cassetta E, Ferreri F, Dal Forno G, et al. 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 2007; 114(12): 1589-94
104. Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005; 64(6): 1040-6
105. Arnal N, Cristalli DO, de Alaniz MJ, Marra CA. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 2010; 1319: 118-30
106. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir, Baldvinsson M, Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. a case-control study. Dement Geriatr Cogn Disord 1998; 9(5): 239-42
107. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989; 35(5-6): 275-82
108. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J 2002; 43(1): 28-32
109. Sedighi B, Shafa MA, Shariati M. A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia 2006; 11: 107-9
110. Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, et al. Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita 2005; 41(2): 197-203
111. Gonzalez C, Martin T, Cacho J, Brenas MT, Arroyo T, Garcia-Berrocal B, et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 1999; 29(7): 637-42
112. Smorgon C, Mari E, Atti AR, Nora DE, Zamboni PF, Calzoni F, et al. Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr Suppl 2004; (9): 393-402
113. Sevim S, Ünal O, Tamer L, Do u O, Özge A. Can serum levels of copper and zinc distinguish Alzheimer's patients from normal subjects? J Neurol Sci 2007; 24(3): 197-205
114. Agarwal R, Kushwaha SS, Tripathi CB, Singh N, Chhillar N. Serum copper in Alzheimer's Disease and vascular dementia. Indian J Clin Biochem 2008; 23(4): 369-74
115. Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 2006; 67(1): 76-82
116. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, et al. Degradation of the Alzheimer disease amyloid beta peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006; 281(26): 17670-80
117. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 2008; 21(3): 367-72
118. Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, et al. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci USA 2005; 102(12): 4294-9
119. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32 Suppl: S94-100
120. Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, Kruger R, et al. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J 2005; 19(13): 1851-3
121. Pall HS, Williams AC, Blake DR, Lunec J, Gutteridge JM, Hall M, et al. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 1987; 2(8553): 238-41
122. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998;67(5 Suppl): 972S-7S
123. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a Japanese family. Ann Neurol 1995; 37(5): 646-56
124. Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS One 2007; 2(3): e334
125. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007; 30: 317-37
126. Roos PM, Vesterberg O, Nordberg M. Metals in motor neuron diseases. Exp Biol Med (Maywood) 2006; 231(9): 1481-7
127. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 364(6435): 362
128. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993; 261(5124): 1047-51
129. Watanabe S, Nagano S, Duce J, Kiaei M, Li QX, Tucker SM, et al. Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic Biol Med 2007; 42(10): 1534-42
130. Trumbull KA, Beckman JS. A role for copper in the toxicity of zinc-deficient superoxide dismutase to motor neurons in amyotrophic lateral sclerosis. Antioxid Redox Signal 2009; 11(7): 1627-39
131. Kapaki E, Zournas C, Kanias G, Zambelis T, Kakami A, Papageorgiou C. Essential trace element alterations in amyotrophic lateral sclerosis. J Neurol Sci 1997; 147(2): 171-5
132. Squitti R, Bressi F, Pasqualetti P, Bonomini C, Ghidoni R, Binetti G, et al. Longitudinal prognostic value of serum free copper in patients with Alzheimer disease. Neurology 2009; 72(1): 50-5
133. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7(9): 779-86
134. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008; 59(1): 43-55
135. Blennow K, Zetterberg H. Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? Alzheimers Res Ther 2010; 2(2): 8
136. Barnham, K.J., Gautier, E.C.L., Kok, G.B., Kippner, G. 8-Hydroxy quinoline derivatives. WO2004007461 (2004)
137. Kok, G.B., Leung, B.K.Y., Gautier, E.C.L., Barnham, K.J. Neurologically-active compounds. WO2004031161 (2004)
138. Salustri C, Barbati G, Ghidoni R, Quintiliani L, Ciappina S, Binetti G, et al. Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol 2010; 121(4): 502-7
139. Babiloni C, Squitti R, Del Percio C, Cassetta E, Ventriglia MC, Ferreri F, et al. Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clin Neurophysiol 2007; 118(6): 1244-60
140. Brewer GJ. Copper toxicity in the general population. Clin Neurophysiol 2010; 121(4): 459-60
141. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57(1): 1-7
142. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107(3): 241-6
143. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007; 595: 197-212
144. Jiao Y, Wilkinson Jt, Pietsch CE, Buss JL, Wang W, Planalp R, et al. Iron chelation in the biological activity of curcu-min. Free Radic Biol Med 2006; 40(7): 1152-60
145. Vander Jagt, D.L., Deck, L.M., Abcouwer, S.F., Orlando, R.A., Royer, R.E., Weber, M.W., Bobrovnikova-marjon, E.V., Hunsaker, L.A. Therapeutic curcumin derivatives. US20070060644 (2007)
146. Lilienfeld, S., Di Mauro, T.M. Iontophoretic delivery of curcumin analogs for the treatment of Alzheimer's disease. US20090325963 (2009)
147. Di Mauro, T.M. Use of nitrogen-containing curcumin analogs for the treatment of Alzheimer's disease. US20090326275 (2009)
148. Di Mauro, T. Intranasally administering curcumin in a bolus of helium gas to treat Alzheimer's disease. US20090087385 (2009).